A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
NCT ID: NCT05566574
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
84 participants
INTERVENTIONAL
2022-09-30
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RP-3500 in Combination With Standard Radiation Therapy
Patients with metastatic cancers with identified mutations in ATM will be enrolled. All patients will receive a standard palliative RT (4Gy x 5 fractions) on Days 1-5 in combination with RP-3500 on Days 1-5. In the first phase of the study, a 3+3 study design will be used to identify a safe dose of RP-3500 (starting at 80 mg QD) in combination with palliative RT.
RP-3500
RP-3500 on Days 1-5.
External Beam Radiotherapy (EBRT)
Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
Pilot subcohort
The primary objective is to assess 6 month local control rate of patients of new metastatic lesions with pathogenic ATM who haves received prior RP-3500 and palliative RT.
RP-3500
RP-3500 on Days 1-5.
External Beam Radiotherapy (EBRT)
Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RP-3500
RP-3500 on Days 1-5.
External Beam Radiotherapy (EBRT)
Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mutation in ATM (deleterious or VUS; somatic or germline; monoallelic or biallelic)
* Note: Homozygous Deletion in the ATM gene will also be allowed
* ECOG performance status 0-2 or KPS equivalent
* Age ≥18 years
* Expected survival greater than 6 months
* Participant or Legally Authorized Representative (LAR) able to provide written informed consent
* Patients of reproductive potential must agree to practice an effective contraceptive method
* Ability to swallow capsules and retain oral medications
* Acceptable organ function at Screening, as evidenced by the following laboratory data:
1. Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault equation or by 24-hour urine collection
2. Total bilirubin ≤1.5 × ULN or \<3.0 × ULN if known Gilbert's disease
3. Serum albumin ≥2.5 g/dL
4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN unless liver metastases are present and thought to be a reason for AST/ALT elevation, in which case they must be ≤5 × ULN
* Acceptable hematologic function at Screening:
1. No red blood cell or platelet transfusions or growth factors within 7 days of the first dose of RP-3500
2. Hemoglobin ≥9.5 g/dL
3. ANC ≥1700 cells/mm\^3
4. Platelet count ≥130,000 cells/mm\^3
* Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for neuropathy, hypothyroidism requiring medication and alopecia can be resolved to Grade ≤2)
* Negative pregnancy test (serum or urine) for women of childbearing potential (WOCBP) at Screening and prior to first study drug. Non-WOCBP is defined as 1) adequate time of amenorrhea for \> 12 months plus adequate FSH level or 2) surgically or anatomically infertile
* Male patients with female partners of childbearing potential and WOCBP must follow a contraception method (oral contraceptives allowed) at least as conservative as Clinical Trial Facilitation Group (CTFG) recommendations during their participation in the study. WOCBP must follow the recommendations until 6 months following last dose of study drug and male patients must follow the recommendations for 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug
Exclusion Criteria
* Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor
* Serious medical co-morbidities precluding radiotherapy
* Pregnant or breast-feeding women
* No other concurrent systemic therapy during the entire duration of protocol treatment. Patients can have other systemic treatments up until the start of protocol treatment. Patients can also have other systemic treatments after the completion of protocol treatments
* Known hypersensitivity to any of the ingredients of RP-3500
* Uncontrolled hypertension (systolic blood pressure \[BP\] ≥160 mmHg; diastolic BP ≥100 mmHg) despite adequate treatment prior to first dose of RP-3500
* Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness. In equivocal cases, patients whose viral load is negative, may be eligible. HIV seropositive patients who are healthy and low risk for AIDS related outcomes could be considered eligible. Eligibility criteria for HIV positive patients should be evaluated and discussed, and will be based on current and past CD4 and T-cell counts, history (if any) of AIDS-defining conditions (eg, opportunistic infections), and status of HIV treatment
* Moderate or severe hepatic impairment (ie, Child-Pugh class B or C)
* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or recent history of myocardial infarction that in the opinion of the investigator will pose an increased risk of rhythm abnormalities
* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (eg, severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (eg, hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
* Current treatment with medications that are well-known to prolong the QT interval
* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol
* Patients who are receiving strong CYP3A inhibitors or inducers, P-gp inhibitors and/or BCRP inhibitors
* Patients with germline homozygous ATM mutations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Repare Therapeutics
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center at Suffolk-Commack (All Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Ezra Rosen, MD,PhD
Role: CONTACT
Phone: 646-888-6955
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nancy Lee, MD
Role: primary
Nancy Lee, MD
Role: primary
Nancy Lee, MD
Role: primary
Nancy Lee, MD
Role: primary
Nancy Lee, MD
Role: primary
Nancy Lee, MD
Role: primary
Ezra Rosen, MD, PhD
Role: backup
Nancy Lee, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-222
Identifier Type: -
Identifier Source: org_study_id